Fig 1: Effect of rAAV2‐OVA transgenic vector containing ERAP1 shRNA on reducing OVA‐specific T‐cell responses. (A) TNF‐α levels in serum were analysed using ELISA (mean ± SD, n = 3). p values were measured using ANOVA and Tukey's post hoc test. (B–C) TNF‐α and IFN‐γ responses upon 5 μg/mL OVA stimulation (+OVA) in splenocytes obtained in mice at 12‐week following rAAV injection. p values were measured by adopting ANOVA and Tukey's post hoc test. (D) The 6‐week‐old C57BL/6 mice were given i.v. injection of PBS, rAAV2‐OVA, rAAV2‐OVA‐ERAP1 shRNA, or rAAV2 empty vector (2 × 1011 GCs/mouse). CD11c+/CD86+ splenocytes collected in 4‐ and 12‐weeks following vector treatment were quantified through flow cytometry. Bar graphs indicate mean ± SD (n = 3). p values were obtained through ANOVA and Holm‐Šídák's post hoc test. (E) TNF‐α mRNA expression in entire spleens was quantified through RT‐qPCR. The data are indicated by mean ± SD (n = 3). p values were measured through ANOVA and Dunnett's post hoc test. *p < 0.05, **p < 0.01, ****p < 0.0001.